Featured Publications
Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis
Farhat L, Behling E, Landeros-Weisenberger A, Levine J, Macul Ferreira de Barros P, Wang Z, Bloch M. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for the treatment of children, adolescents, and young adults with Tourette's syndrome: a systematic review and network meta-analysis. The Lancet Child & Adolescent Health 2022, 7: 112-126. PMID: 36528030, DOI: 10.1016/s2352-4642(22)00316-9.Peer-Reviewed Original ResearchConceptsSecond-generation antipsychotic drugsMedication categoriesAntipsychotic drugsModerate certaintyIndividual medicationsTourette syndromePharmacological interventionsLow certaintyWHO International Clinical Trials Registry PlatformInternational Clinical Trials Registry PlatformSystematic reviewClinical Trials Registry PlatformChoice of medicationCochrane Central RegisterNetwork meta-analysis frameworkTrials Registry PlatformRandom-effects networkTerms of tolerabilityCertainty of evidenceClinical practice guidelinesComorbid attention deficit hyperactivity disorderStandardised mean differenceTreatment of childrenAttention deficit hyperactivity disorderWeb of ScienceA systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Molecular Psychiatry 2006, 11: 622-632. PMID: 16585942, DOI: 10.1038/sj.mp.4001823.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntipsychotic AgentsBasal Ganglia DiseasesBenzodiazepinesComorbidityDepressive DisorderDibenzothiazepinesDouble-Blind MethodDrug ResistanceDrug Therapy, CombinationHaloperidolHumansMiddle AgedObsessive-Compulsive DisorderOlanzapinePatient DropoutsQuetiapine FumarateRandomized Controlled Trials as TopicRisperidoneSelective Serotonin Reuptake InhibitorsTic DisordersTreatment OutcomeConceptsSerotonin reuptake inhibitorsAntipsychotic augmentationAbsolute risk differenceObsessive-compulsive disorderComorbid ticsOCD patientsTreatment responseSystematic reviewTreatment-refractory obsessive-compulsive disorderTreatment-refractory OCD patientsRefractory obsessive-compulsive disorderDouble-blind trialEfficacy of quetiapineTreatment-refractory OCDCochrane Central RegisterMeaningful treatment responseProportion of subjectsEfficacy of haloperidolRandomized control trialObsessive-compulsive disorder patientsSRI monotherapyAdequate trialCentral RegisterControlled TrialsReuptake inhibitors
2020
Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study
Taylor JH, Appel S, Eli M, Alexander-Bloch A, Maayan L, Gur RE, Bloch MH. Time to Clinical Response in the Treatment of Early Onset Schizophrenia Spectrum Disorders Study. Journal Of Child And Adolescent Psychopharmacology 2020, 31: 46-52. PMID: 32633541, PMCID: PMC7891207, DOI: 10.1089/cap.2020.0030.Peer-Reviewed Original ResearchConceptsClinical Global Impression-ImprovementClinical responseEarly Onset Schizophrenia Spectrum Disorders StudySymptom improvementWeek 8Early-onset schizophrenia spectrum disordersClinical response timeWeeks of treatmentProportional hazards regressionDisorders StudyTime courseSchizophrenia spectrum disordersClinical nonresponseMedication differencesClinical respondersTreatment initiationClinical nonrespondersMedian timeHazards regressionAntipsychotic treatmentEarly improvementSchizoaffective disorderClinical judgmentMore weeksYouth ages 8Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders
Zhou MS, Nasir M, Farhat LC, Kook M, Artukoglu BB, Bloch MH. Meta-analysis: Pharmacologic Treatment of Restricted and Repetitive Behaviors in Autism Spectrum Disorders. Journal Of The American Academy Of Child & Adolescent Psychiatry 2020, 60: 35-45. PMID: 32387445, DOI: 10.1016/j.jaac.2020.03.007.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsPlacebo-controlled trialPharmacological treatmentPharmacological agentsAvailable pharmacological agentsAutism spectrum disorderSerotonin reuptake inhibitorsStandardized mean differenceStandardized study designsTreatment of ASDPharmacologic treatmentPrimary outcomeReuptake inhibitorsAntipsychotic medicationSpecific assessment toolsFolinic acidSpectrum disorderModest benefitRepetitive behaviorsMean differenceStudy designSmall effect sizesIndividual studiesTrialsPlacebo
2019
The Potential of Cannabinoid-Based Treatments in Tourette Syndrome
Artukoglu BB, Bloch MH. The Potential of Cannabinoid-Based Treatments in Tourette Syndrome. CNS Drugs 2019, 33: 417-430. PMID: 30977108, DOI: 10.1007/s40263-019-00627-1.Peer-Reviewed Original ResearchConceptsTourette syndromeCannabinoid systemAdult populationPositive urine drug screenBiological rationaleCannabinoid-based treatmentsPotential of cannabinoidsTourette syndrome populationsPlacebo-controlled trialTreatment of ticsUrine drug screensNovel pharmacological treatmentsCannabis-derived compoundsStrong biological rationaleCurrent evidence baseComprehensive literature searchDevelopmental adverse effectsRefractory patientsSafety profilePharmacological treatmentClinical trialsTic disordersUncertain efficacyFurther trialsSyndrome population
2018
Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study
Taylor JH, Jakubovski E, Gabriel D, Bloch MH. Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. Journal Of Child And Adolescent Psychopharmacology 2018, 28: 474-484. PMID: 29920116, PMCID: PMC6154761, DOI: 10.1089/cap.2017.0147.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAntipsychotic AgentsFemaleHumansMaleOlanzapinePsychiatric Status Rating ScalesRisk FactorsRisperidoneSchizophreniaWeight GainMeta regression: Relationship between antipsychotic receptor binding profiles and side-effects
Olten B, Bloch MH. Meta regression: Relationship between antipsychotic receptor binding profiles and side-effects. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2018, 84: 272-281. PMID: 29410000, DOI: 10.1016/j.pnpbp.2018.01.023.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsHumansMeta-Analysis as TopicProtein BindingReceptors, NeurotransmitterRegression AnalysisSchizophreniaConceptsRisk of sedationExtrapyramidal side effectsM4 receptorsReceptor binding profileWeight gainAntipsychotic medicationSide effectsGeneric inverse variance methodReceptor affinityAffinity of antipsychoticsIndividual antipsychotic medicationsInverse variance methodTreatment of schizophreniaExtrapyramidal symptomsQTc prolongationM1 receptorsProlactin increaseQT prolongationAntipsychotic agentsH1 receptorsHigh riskMedicationsSedationBinding profileReceptors
2017
Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis
van Schalkwyk GI, Lewis AS, Beyer C, Johnson J, van Rensburg S, Bloch MH. Efficacy of antipsychotics for irritability and aggression in children: a meta-analysis. Expert Review Of Neurotherapeutics 2017, 17: 1045-1053. PMID: 28847182, DOI: 10.1080/14737175.2017.1371012.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAggressionAntipsychotic AgentsChildChild Behavior DisordersHumansIrritable MoodOutcome Assessment, Health CareConceptsDegree of sedationSubgroup analysisDiagnostic indicationsOverall dose effectEfficacy of risperidoneStratified subgroup analysisEfficacy of antipsychoticsIndividual antipsychotic agentsChoice of agentRange of diagnosesSpecific medicationsAntipsychotic efficacyAntipsychotic agentsAntipsychotic doseClinical dataOverall effect sizeAntipsychoticsNegative psychosocial outcomesIrritabilityPsychosocial outcomesEfficacyDiagnosisDose effectSedationRisperidoneAntipsychotics for aggression in adults: A meta-analysis
van Schalkwyk GI, Beyer C, Johnson J, Deal M, Bloch MH. Antipsychotics for aggression in adults: A meta-analysis. Progress In Neuro-Psychopharmacology And Biological Psychiatry 2017, 81: 452-458. PMID: 28754408, DOI: 10.1016/j.pnpbp.2017.07.019.Peer-Reviewed Original ResearchConceptsTreatment of aggressionAntipsychotic medicationNon-pharmacologic interventionsEffect sizeChoice of agentSignificant dose effectSignificant morbidityCochrane LibraryAntipsychotic agentsDopamine antagonistsPsychiatric illnessIrritable moodMultiple diagnosesClinical decisionAntipsychoticsSpecific agentsSearch termsSmall effect sizesDiagnosisDose effectMedicationsSymptom dimensionsAggressive behaviorTreatmentAdultsPredictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study
Gabriel D, Jakubovski E, Taylor JH, Artukoglu BB, Bloch MH. Predictors of treatment response and drop out in the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Psychiatry Research 2017, 255: 248-255. PMID: 28595147, DOI: 10.1016/j.psychres.2017.05.038.Peer-Reviewed Original ResearchObsessive-Compulsive Disorder: Advances in Diagnosis and Treatment
Hirschtritt ME, Bloch MH, Mathews CA. Obsessive-Compulsive Disorder: Advances in Diagnosis and Treatment. JAMA 2017, 317: 1358-1367. PMID: 28384832, DOI: 10.1001/jama.2017.2200.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment of OCDReuptake inhibitorsBehavioral therapySystematic reviewFirst-line pharmacologic interventionPreferred initial treatment strategyTreatment-resistant obsessive-compulsive disorderInitial treatment strategyPrimary care settingTreatment-resistant casesDiagnosis of OCDFirst-line interventionEfficacy of neurolepticsDeep brain stimulationComputer-based cognitive behavioral therapyCase seriesPharmacologic interventionsAdjunctive useTreatment optionsTreatment advancesNeuromodulatory approaches
2015
Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial.
Jakubovski E, Carlson JP, Bloch MH. Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial. The Journal Of Clinical Psychiatry 2015, 76: 1535-45. PMID: 26581028, DOI: 10.4088/jcp.14m09320.Peer-Reviewed Original ResearchConceptsIntervention Effectiveness (CATIE) trialTreatment outcomesClinical Antipsychotic TrialsBaseline characteristicsTreatment continuationCATIE trialAntipsychotic pharmacotherapyPrognostic subgroupsEffectiveness trialAntipsychotic TrialsLogistic regressionROC analysisMonths of treatmentImportant treatment outcomesDSM-IV diagnosisPatients' social isolationNegative Syndrome ScaleSocial isolationPoor outcomeZiprasidone treatmentAntipsychotic treatmentComorbid depressionSide effectsPsychosocial factorsSyndrome ScaleObstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy
Coughlin CG, Blackwell KA, Bartley C, Hay M, Yonkers KA, Bloch MH. Obstetric and Neonatal Outcomes After Antipsychotic Medication Exposure in Pregnancy. Obstetrics And Gynecology 2015, 125: 1224-1235. PMID: 25932852, PMCID: PMC4418034, DOI: 10.1097/aog.0000000000000759.Peer-Reviewed Original ResearchConceptsAdverse birth outcomesGestational-age birthsAntipsychotic exposureNeonatal outcomesCohort studyBirth outcomesAntipsychotic medicationMajor malformationsBirth weightOdds ratioAntipsychotic medication exposureNeonatal birth weightPooled odds ratioPotential risk factorsUnexposed pregnanciesMedication exposurePreterm deliveryGestational ageAntipsychotic treatmentElective terminationPossible confoundersReproductive ageRisk factorsSpontaneous abortionSTUDY SELECTIONAssessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children
Bloch MH, Storch EA. Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children. Journal Of The American Academy Of Child & Adolescent Psychiatry 2015, 54: 251-262. PMID: 25791142, PMCID: PMC4460245, DOI: 10.1016/j.jaac.2015.01.011.Peer-Reviewed Original ResearchConceptsTreatment-refractory obsessive-compulsive disorderPediatric obsessive-compulsive disorderSelective serotonin reuptake inhibitorsObsessive-compulsive disorderCognitive behavioral therapyTreatment-Refractory ObsessivePharmacological treatment optionsSide effect profileSerotonin reuptake inhibitorsTreatment of adultsGlutamate-modulating agentsLittle evidence-based dataEvidence of efficacyEvidence-based dataPediatric OCD patientsOCD symptomsAntipsychotic augmentationSSRI dosagesPediatric patientsReuptake inhibitorsEffect profilePediatric populationTreatment optionsPractice guidelinesEffective treatment
2013
Meta-analysis: pharmacological treatment of pathological gambling
Bartley CA, Bloch MH. Meta-analysis: pharmacological treatment of pathological gambling. Expert Review Of Neurotherapeutics 2013, 13: 887-894. PMID: 23952195, DOI: 10.1586/14737175.2013.814938.Peer-Reviewed Original ResearchMeSH KeywordsAntipsychotic AgentsGamblingHumansNaltrexoneNarcotic AntagonistsRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsConceptsStandardized mean differenceReported efficacyPharmacological treatmentOpiate antagonistPathological gamblingPlacebo-controlled trialBenefits of medicationsCurrent trial dataFixed-effects modelTreat principleNon-significant effect sizeITT principlePharmacological agentsMeta-AnalysisTrial dataPublication biasSecondary analysisPlaceboMean differenceAntagonistTrialsMedicationsEfficacyYear of publicationEffect sizeLONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER
Bloch MH, Green C, Kichuk SA, Dombrowski PA, Wasylink S, Billingslea E, Landeros‐Weisenberger A, Kelmendi B, Goodman WK, Leckman JF, Coric V, Pittenger C. LONG‐TERM OUTCOME IN ADULTS WITH OBSESSIVE‐COMPULSIVE DISORDER. Depression And Anxiety 2013, 30: 716-722. PMID: 23532944, PMCID: PMC3932438, DOI: 10.1002/da.22103.Peer-Reviewed Original ResearchConceptsLong-term outcomesObsessive-compulsive disorderEvidence-based treatmentsAdult OCD patientsLong-term clinical outcomesSymptom severitySerotonin reuptake inhibitor medicationsOCD patientsPlacebo-controlled trialSerotonin reuptake inhibitorsReuptake inhibitor medicationsPercent of subjectsInitial responseSymptom dimensionsLater symptom severityOCD symptomsSignificant OCD symptomsOCD symptom dimensionsAdult patientsClinical characteristicsClinical improvementEligible subjectsPartial respondersInhibitor medicationReuptake inhibitors
2012
Systematic Review of Proinflammatory Cytokines in Obsessive-Compulsive Disorder
Gray SM, Bloch MH. Systematic Review of Proinflammatory Cytokines in Obsessive-Compulsive Disorder. Current Psychiatry Reports 2012, 14: 220-228. PMID: 22477442, PMCID: PMC3625952, DOI: 10.1007/s11920-012-0272-0.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAntipsychotic AgentsHumansInterleukin-1betaInterleukin-6Obsessive-Compulsive DisorderTumor Necrosis Factor-alphaConceptsIL-6 levelsStratified subgroup analysisTNF-α levelsObsessive-compulsive disorderProinflammatory cytokinesComorbid depressionMedication useIL-6Subgroup analysisCerebrospinal fluid cytokine levelsElevated TNF-α levelsPlasma IL-6 levelsLower plasma IL-6 levelsIL-1β levelsTumor necrosis factorCytokine levelsEffect of ageSerum levelsPsychotropic medicationsPlasma levelsNecrosis factorInclusion criteriaImmune functionPotential confoundingSystematic review
2009
Trichotillomania Across the Life Span
Kratochvil C, Bloch M. Trichotillomania Across the Life Span. Journal Of The American Academy Of Child & Adolescent Psychiatry 2009, 48: 879-883. PMID: 19692854, DOI: 10.1097/chi.0b013e3181ae09f3.Peer-Reviewed Original ResearchAcetylcysteineAdolescentAdultAge FactorsAntipsychotic AgentsBehavior TherapyChildChild, PreschoolCommunity Mental Health ServicesExcitatory Amino Acid AgentsHumansNaltrexoneNarcotic AntagonistsRandomized Controlled Trials as TopicSelective Serotonin Reuptake InhibitorsTreatment OutcomeTrichotillomania
2008
Emerging treatments for Tourette’s disorder
Bloch MH. Emerging treatments for Tourette’s disorder. Current Psychiatry Reports 2008, 10: 323. PMID: 18627671, DOI: 10.1007/s11920-008-0052-z.Peer-Reviewed Original ResearchConceptsTourette's disorderRepetitive transcranial magnetic stimulationChildhood-onset neuropsychiatric disorderHabit reversal therapyDeep brain stimulationTranscranial magnetic stimulationReversal therapyVocal ticsCurrent treatmentSevere symptomsMagnetic stimulationBrain stimulationSignificant disabilityNeuropsychiatric disordersEvidence baseDisordersTreatmentStimulationTherapySymptomsMultiple motors
2006
Adulthood Outcome of Tic and Obsessive-Compulsive Symptom Severity in Children With Tourette Syndrome
Bloch MH, Peterson BS, Scahill L, Otka J, Katsovich L, Zhang H, Leckman JF. Adulthood Outcome of Tic and Obsessive-Compulsive Symptom Severity in Children With Tourette Syndrome. JAMA Pediatrics 2006, 160: 65-69. PMID: 16389213, PMCID: PMC2291298, DOI: 10.1001/archpedi.160.1.65.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdrenergic alpha-AgonistsAdultAntipsychotic AgentsAttention Deficit Disorder with HyperactivityBipolar DisorderChildDepressive DisorderFemaleFollow-Up StudiesHumansIntelligence TestsMaleObsessive-Compulsive DisorderProspective StudiesSchizophreniaSelective Serotonin Reuptake InhibitorsSeverity of Illness IndexTic DisordersTourette SyndromeConceptsTic symptomsTourette syndromeTic severitySymptom severityObsessive-compulsive disorderBaseline clinical measurementsChildhood-onset neuropsychiatric disorderOCD symptomsPercent of patientsProspective cohort studyPercent of subjectsOutpatient specialty clinicsThird of childrenThird of adultsAge 14 yearsStructured clinical evaluationCohort studyClinical courseComplete resolutionClinical evaluationPhonic ticsSpecialty clinicFollow-up interviewObsessive-compulsive symptom severityAverage age